Preventing Mother-to-Child Transmission of Hepatitis B

Hepatitis B remains one of the most important preventable causes of chronic liver disease worldwide. When infection passes from a pregnant person to an infant during pregnancy or around delivery, the newborn has a high risk of developing lifelong hepatitis B. Early prevention therefore protects two generations: the parent receives appropriate care, and the child avoids a chronic infection that can later lead to cirrhosis or liver cancer.

Effective prevention depends on a sequence of actions rather than a single intervention. Antenatal screening identifies hepatitis B surface antigen-positive mothers, viral-load testing helps determine whether antiviral therapy is needed, and timely newborn immunization blocks exposure at birth. Follow-up confirms that protection has worked.

These measures fit naturally within the coordinated perinatal care discussed through the FAOPS 2020 website, which brought together professionals in maternal, fetal, and neonatal medicine. Although the planned Tokyo congress was canceled in 2020, the clinical priorities remain relevant wherever maternity and newborn services are delivered.

Why Perinatal Hepatitis B Still Matters

Hepatitis B virus can spread through blood and body fluids. During childbirth, an infant may encounter infected blood or secretions, making the peripartum period a major point of transmission. Infection acquired in infancy is particularly dangerous because the immature immune response allows the virus to persist. Many infected children have no symptoms, yet they may carry and transmit the virus for decades.

A positive hepatitis B surface antigen, or HBsAg, result indicates current infection and should trigger a documented prevention pathway. The result does not by itself show how infectious a person is, whether liver inflammation is present, or whether antiviral treatment is required. Additional assessment may include hepatitis B e antigen, alanine aminotransferase, and quantitative HBV DNA testing.

Prevention also has a public-health dimension. Identifying infection during pregnancy creates an opportunity to test and vaccinate household members, link the mother to liver care, and ensure that every future pregnancy begins with a known hepatitis B status. Clear communication helps prevent stigma and supports informed decisions about delivery, feeding, and infant care.

Screening During Pregnancy

Universal HBsAg screening during every pregnancy is preferable to testing only people considered high risk. Risk-based approaches can miss infection because many people do not know when or how they acquired the virus. Screening should occur early in antenatal care, with repeat testing later in pregnancy when clinically indicated or when local policy recommends it.

A positive result should be recorded in the maternity notes and communicated to the delivery and newborn teams. If the result is unknown when labor begins, testing should be arranged urgently, since the infant’s first vaccine dose should not wait for a lengthy diagnostic process. Rapid coordination is especially important when a patient transfers between facilities.

Pregnancy care must also account for emotional wellbeing. A diagnosis can create anxiety about the baby, relationships, and future health. Resources on maternal mental health illustrate why respectful counseling and psychosocial support belong alongside laboratory testing. Clinicians should explain that hepatitis B is manageable, that prevention is highly effective, and that confidential care is available.

Reducing Transmission Before Birth

Most infants born to mothers with chronic hepatitis B can be protected through vaccination and, when indicated, hepatitis B immunoglobulin after delivery. However, maternal antiviral therapy can further reduce the risk when the mother has a very high HBV DNA level. Current international guidance commonly considers tenofovir disoproxil fumarate during late pregnancy when HBV DNA exceeds approximately 200,000 IU/mL, though local protocols, availability, and specialist judgment must guide treatment.

HBV DNA testing is therefore a practical part of prevention. It provides a clearer estimate of transmission risk than HBeAg status alone and helps identify patients who may benefit from antiviral prophylaxis. Testing should be arranged early enough to allow counseling, prescription, and coordination with obstetric and neonatal services. The treating team should also assess liver health and determine whether antiviral medication is needed for the mother’s own long-term benefit.

Antiviral therapy should be explained as one component of a broader prevention package. It does not replace the birth dose, HBIG when indicated, or completion of the infant vaccine schedule. Providers should document the planned start and stop dates, review medication access, and arrange follow-up after delivery.

Protection at Birth and Afterward

The newborn vaccine is time-sensitive. For an infant exposed to maternal hepatitis B, vaccination should be administered as soon as possible after birth, preferably within 12 hours. Hepatitis B immunoglobulin is commonly recommended for infants of HBsAg-positive mothers, particularly where the risk of exposure is substantial. The products should be given at separate injection sites.

The infant must then receive the remaining doses according to the national immunization schedule. Combination vaccines may be used when appropriate, but the birth dose should meet the requirements for hepatitis B prevention. A written record should travel with the family if the baby receives care at more than one facility.

Breastfeeding is generally compatible with hepatitis B prevention once the infant has received the recommended immunoprophylaxis. Mothers should receive practical help with feeding and should not be discouraged solely because of their hepatitis B status. If nipples are cracked or bleeding, temporary clinical advice may be needed until they heal.

Cesarean birth is not routinely recommended solely to prevent hepatitis B transmission. The most reliable protection comes from maternal screening, appropriate antiviral management, and immediate newborn immunization. Standard obstetric indications should determine the mode of delivery.

Family-Centered Follow-Up

Prevention does not end at discharge. Families need a clear schedule for vaccine doses, pediatric visits, and post-vaccination serologic testing. For infants born to HBsAg-positive mothers, testing for HBsAg and anti-HBs is generally performed at 9–12 months of age, or according to national guidance and the timing of the final vaccine dose. Testing too early can produce misleading results from passive antibodies or incomplete immune response.

Results should be explained carefully. A protective anti-HBs level with a negative HBsAg result indicates successful immunization. A negative anti-HBs result may require clinical review and, in some circumstances, revaccination. A positive HBsAg result requires referral for pediatric evaluation and long-term monitoring.

Follow-up systems work best when responsibility is assigned before the family leaves the birth facility. Electronic reminders, immunization registries, community health workers, and direct communication between maternity and primary-care teams can reduce missed appointments. This continuity is as important to child health as specialized neonatal follow-up, including the developmental surveillance described in discussions of preterm infant outcomes.

Household contacts should be offered hepatitis B testing and vaccination when appropriate. Partners, older children, and other people living with the mother may have been exposed, but household transmission is preventable through vaccination, safe handling of blood, and avoiding the sharing of razors or toothbrushes.

Practical Priorities for Care Teams

A reliable program uses standardized pathways that connect antenatal clinics, laboratories, labor wards, pharmacies, immunization services, and primary care. Every positive HBsAg result should generate a visible alert, a documented plan, and a clear handoff. Facilities should also monitor vaccine and HBIG supplies, staff training, cold-chain performance, and the percentage of exposed infants receiving timely prophylaxis.

Counseling should use plain language and protect confidentiality. Clinicians can explain that a positive test does not reflect personal character, that many people live well with chronic hepatitis B, and that the newborn can be strongly protected. Interpreters and culturally appropriate materials are valuable when language or health-literacy barriers affect understanding.

• Screen every pregnant patient for HBsAg according to national guidance.
• Arrange HBV DNA testing and specialist review for HBsAg-positive patients.
• Prepare the newborn team before delivery when maternal infection is known.
• Administer the birth vaccine promptly and HBIG when indicated and available.
• Track the full vaccine series and post-vaccination serologic testing.

Data collection can reveal where prevention is failing. Useful indicators include screening coverage, the proportion of positive patients with documented HBV DNA results, birth-dose timing, HBIG administration, series completion, and protective antibody rates. Reviewing these measures at maternity and neonatal meetings turns individual successes into a dependable system.

Every pregnancy is an opportunity to interrupt hepatitis B transmission. Put universal screening, coordinated antiviral assessment, timely newborn immunization, and long-term follow-up into routine practice so that fewer children begin life carrying a preventable infection.